Phase 2 study of 99mTc-Trofolastat SPECT/CT to identify and localize prostate cancer in intermediate- and high-risk patients undergoing radical prostatectomy and extended pelvic LN dissection
The Journal of Nuclear Medicine Sep 09, 2017
Goffin K, et al. - An inspection was conducted of the performance of 99mTc-trofolastat SPECT/CT in patients with intermediate- and high-grade prostate cancer (PCa), before radical prostatectomy and extended pelvic lymph node (LN) dissection, with histopathology as the gold standard. It was observed that 99mTc-trofolastat SPECT/CT detected PCa with high sensitivity in patients with intermediate- and high-risk PCa compared with histology. It exhibited the potential of being used as a surrogate marker for Gleason scores (GS) and predict LN involvement (LNI).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries